Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis Authors: Sean R Van Helden, Ashlan J Kunz Coyne, Sara Alosaimy, Kyle C Molina, S Lena Kang-Birken, Justin Andrade, Madeline A King, Kimberly C Claeys, Athena L V Hobbs, Nicholson B Perkins III, Jazmin Agee, Alaina DeKerlegand, Mark Biagi, Michael P Veve, Serina Tart, Tristan Gore, Bruce M Jones, Benjamin M Pullinger, Melanie Rae Schrack, Reese Cosimi, Shelbye R Herbin, Chloe Judd, Mohammed Al Musawa, Michael J Rybak Published: 2025 ABSTRACT AbstractBackgroundInfections due to Enterococcus faecalis and Enterococcus faecium are common in the hospital setting and carry a high risk for morbidity and mortality. Furthermore, the incidence of drug-resistant phenotypes, such as vancomycin-resistant Enterococci (VRE) and daptomycin non-susceptible strains, is increasing. Eravacycline (ERV) is a novel tetracycline antibiotic approved for the treatment of complicated intra-abdominal infections and possesses a broad spectrum of activity across both Gram-positive and Gram-negative organisms, including VRE, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Enterobacterales.MethodsWe conducted a subgroup analysis assessing the real-world efficacy and safety of ERV for the treatment of enterococcal infections. Adult patients who received ERV for ≥ 72 h for E. faecalis or E. faecium infections were included. The primary outcome of clinical cure was defined as resolution or improvement of infection-related signs and/or symptoms.ResultsA total of 100 patients were included in the analysis. E. faecalis and E. faecium were present in 44% and 58% of patients, respectively, and 49% of all isolates were VRE. The most prevalent infection types were intra-abdominal, skin/soft tissue, and osteomyelitis, and a majority (80%) of infections were polymicrobial. Clinical cure was achieved in 77% of patients. Thirty-day mortality was 17% and 30-day infection-related mortality was 12%. Thirty-day hospital readmission rate was 14%, and microbiological recurrence occurred in 4% of patients. Treatment-emergent adverse events occurred in 8% of patients, with 2% of patients requiring discontinuation of ERV.ConclusionThis study describes the real-world safety and efficacy of ERV for the treatment of enterococcal infections.Keywords: Eravacycline, Enterococcus, Enterococcus faecalis, Enterococcus faecium, Vancomycin-resistant enterococcus, VRE, Tetracycline Background Enterococcal infections carry a high risk for morbidity and mortality in the hospital setting and are the second leading causative group of organisms in nosocomial infections after Staphylococcus spp [1]. Enterococcus spp. are frequently identified as causes of complicated urinary tract infections, complicated intra-abdominal infections (cIAI), bacteremia, and endocarditis [2, 3]. As commensals that exist within the typical human gastrointestinal flora, enterococci exhibit a notable capacity for persistence via rapidly adaptive metabolism and host immune evasion [4]. Persistently positive blood cultures beyond 72 h despite appropriate antimicrobial therapy occurs in 10–15% of enterococcal bacteremia cases and is associated with increased mortality [5, 6]. While enterococci are generally less virulent than Staphylococcus or Streptococcus spp., their ability to persist and form extensive biofilms refractory to eradication by antimicrobials on prosthetic materials (particularly E. faecalis) complicates the treatment of medical device and prosthetic joint infections (PJI) [7]. While vancomycin remains a first-line treatment option for many enterococcal infections, the incidence of vancomycin-resistant Enterococci (VRE) is increasing [8]. Currently, the United States Centers for Disease Control and Prevention (CDC) identify VRE as a high-priority pathogen [8]. Nearly 80% of E. faecium and 9% of E. faecalis isolates in clinical settings are vancomycin resistant [1]. Vancomycin resistance in enterococcal bloodstream infections is associated with increased mortality compared with vancomycin-susceptible isolates and incurs an additional $77,000 in excess costs per patient compared to those who are uninfected [9, 10]. Compounding these issues, the incidence of resistance to daptomycin, a first-line treatment option for VRE, is becoming increasingly prevalent [11]. The elimination of both vancomycin and daptomycin from our armamentarium severely limits the therapeutic options available for the treatment of these organisms, particularly in E. faecium, where ampicillin resistance is commonplace [12]. The use of linezolid for infections caused by VRE is complicated by contraindicating drug interactions and myelosuppression, particularly with prolonged durations [13, 14]. Moreover, production of quinupristin-dalfopristin was discontinued in 2022 and is no longer available for therapeutic use, further reducing the already limited number of treatment options for VRE [15]. While novel long-acting glycopeptides such as dalbavancin and oritavancin appear to be promising for the treatment of enterococcal infections, clinical data supporting their use in these infections are limited to case reports and smaller observational studies [16–22]. Furthermore, the efficacy of these agents against resistant phenotypes may be of concern. Dalbavancin, for instance, has minimal activity against vanA-possessing enterococci [23]. Conversely, oritavancin appears to have strong in vitro activity against vancomycin-resistant E. faecium, however, its activity against VanA-producing E. faecalis appears to be reduced [24, 25]. These challenges necessitate further investigation into novel therapeutic alternatives for the treatment of enterococcal infections. Eravacycline (ERV) is a novel tetracycline antibiotic authorized for use in the United States and the European Union for the treatment of cIAI [26, 27]. ERV possesses a broad spectrum of activity covering many Gram-positive, Gram-negative, and anaerobic bacterial species (including Clostridioides difficile) [28]. Furthermore, ERV is active against many multidrug-resistant (MDR) organisms, including VRE, methicillin-resistant Staphylococcus aureus (MRSA), and extended spectrum β-lactamase (ESBL)-producing and carbapenemase-producing Enterobacterales (CPE). While previous generations of tetracyclines also have broad spectra, tetracycline-specific acquired resistance may render these agents ineffective. ERV improves upon previous tetracycline generations by overcoming resistance mechanisms that render them ineffective. ERV is generally stable against tetracycline-specific efflux and maintains activity against organisms producing common ribosomal protection proteins, including TetM [28]. The efficacy of ERV was demonstrated in two phase III clinical trials: IGNITE1 and IGNITE4. IGNITE1 demonstrated the non-inferiority in clinical response at the test-of-cure (TOC) visit of intravenous ERV compared to ertapenem for the treatment of cIAI [29]. Subsequently, IGNITE4 evaluated the safety and efficacy of intravenous ERV compared to meropenem for the treatment of cIAI [30]. Aligning with the results of IGNITE1, ERV demonstrated non-inferiority to meropenem for clinical response at the TOC visit. There was a total of 110 patients with enterococcal infections across both trials, and clinical response was observed in 84.5% of these cases. To assess the real-world application, efficacy, and safety of ERV following its approval in the United States, our group conducted a multicenter, retrospective cohort study assessing adult patients who received ERV for ≥ 72 h for any infection [31]. Of the 416 patients included, 42.5% were admitted to the intensive care unite (ICU), and 49.5% had hospital-acquired infections. Clinical success was achieved in 75.7% of patients. With regards to safety, treatment-emergent adverse events (TEAEs) occurred in 9.4% of patients. While this and other studies have described the safe and effective use of ERV in the real-world setting, there are few data directly assessing its efficacy in treating enterococcal infections, including VRE. In this subpopulation analysis, we describe the real-world efficacy of ERV in treating infections due to Enterococcus faecalis and/or Enterococcus faecium, including VRE. Methods This multicenter, real-world, retrospective cohort study was conducted across 15 centers in the United States in patients with enterococcal infections from October 2018 to January 2025. Eligible patients were at least 18 years old and received ERV for ≥ 72 continuous hours in the hospital setting for an infection caused by E. faecalis and/or E. faecium, isolated in culture. This subpopulation analysis was derived from a broader retrospective cohort study including 416 patients assessing the safety and efficacy of ERV for the treatment of various infection types and organisms from October 2018 to August 2022. An extended eligibility screening was conducted to identify additional cases occurring after the analysis of the previously published study. The primary outcome was clinical cure, defined as resolution or improvement of infection-related signs and/or symptoms, including leukocytosis, fever, or as documented in physician progress notes. Secondary outcomes comprised 30-day all-cause mortality, 30-day infection-related mortality, 30-day readmission, 60-day readmission, infection-related readmission to the hospital, and incidence of TEAEs attributable to ERV. The study methodology and waiver of consent was approved by the institutional review board at each participating site in addition to the host site (Wayne State University) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Study data were collected from institutional electronic medical records and managed using REDCap electronic data capture tools hosted at Wayne State University [32, 33]. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies. Statistical analysis was performed using SPSS Statistics software version 30.0 (IBM Corp., Armonk, NY, USA) [34]. Analysis comprised descriptive statistics, including measures of central tendency and dispersion where appropriate. Illness severity was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score [35]. Comorbidity burden was evaluated using the Charlson Comorbidity Index (CCI) [36]. Antimicrobial susceptibility was assessed using breakpoints published by the Clinical and Laboratory Standards Institute unless indicated [37]. Results A total of 100 patients met the criteria for inclusion in this analysis. Patient baseline characteristics are outlined in Table 1. Included patients had a median age of 61.0 years (interquartile range [IQR]: 52.0–69.0) and 53% were male. A majority of patients were White (60%) or Black (30%) and the median body mass index (BMI) was 26.5 (IQR 23.2–31.4). Patients had a median Charleston Comorbidity Index of 4.5 (IQR 2.0–7.0) and 41% had diabetes. Other prevalent comorbidities included peripheral vascular disease (21%), malignancy (19%), and moderate to severe chronic kidney disease (18%). 19% of patients were immunosuppressed, and 88% had risk factors for the development of infection due to MDR organisms. ICU admission was common, with 59% of patients having at least one ICU admission during their hospitalization, with a median total ICU length of stay of 23.5 days (IQR 12.0–58.8). The median APACHE II score was 14.5 (IQR 8.3–19.8), and the median hospital length of stay was 30.0 days (IQR 14.3–46.8). Table 1Baseline characteristics (n = 100)aParameterValueAge (years) (median, IQR)61.0 (52.0–69.0)Male53 (53.0) Race / Ethnicity White61 (61.0) Black30 (30.0) Hispanic6 (6.0) Asian2 (2.0) Other1 (1.0)BMI (kg/m2) (median, IQR)26.5 (23.2–31.4)Obese (BMI ≥ 30 kg/m2)28 (28.0) Admission source Home61 (61.0) NH/LTC19 (19.0) Transfer from outside hospital15 (15.0) Others5 (5.0) Severity scores APACHE II score (median, IQR)14.5 (8.3–19.8) Charlson Comorbidity Index (median, IQR)4.5 (2.0–7.0) Comorbid conditions Diabetes41 (41.0) Peripheral vascular disease21 (21.0) Malignancy19 (19.0) Moderate to severe chronic kidney diseaseb18 (18.0) COPD15 (15.0) Heart failure11 (11.0) Moderate to severe liver disease11 (11.0) Cerebrovascular disease9 (9.0) Chronic dialysis6 (6.0) Clostridioides difficilec3 (3.0) IV drug use3 (3.0) Immunosuppression d 19 (19.0) Cytotoxic chemotherapy8 (8.0) High-dose corticosteroids6 (6.0) Neutropenia5 (5.0) Functional or surgical splenectomy1 (1.0) Patients with MDR risk factors 88 (88.0) ≥24 h antibiotics within 90 days53 (53.0) ≥48 h hospitalization within 90 days65 (65.0) Prior infection with resistant organism25 (25.0) Surgery ≤ 30 days before index culture30 (30.0) NH/LTC resident17 (17.0) Home wound care12 (12.0) Colonization with resistant organism(s)9 (9.0) Chronic dialysis6 (6.0) Home infusion3 (3.0)a Data presented as number (%) or median (IQR), as appropriateb Kidney Disease Outcomes Quality Initiative (KDOQI) chronic kidney disease stages 3–5 or GFR < 60 mL/min or on chronic dialysisc History of Clostridioides difficile infectiond Immunosuppression factors: neutropenia (absolute neutrophil count < 500); splenectomy (functional or surgical); high dose corticosteroids (≥ prednisone 20 mg/day or equivalent)Abbreviations: BMI, body mass index; LTAC, long-term acute care; NH/LTC, nursing home/long-term care facility; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, sequential organ failure assessment; COPD, chronic obstructive pulmonary disease Baseline characteristics (n = 100)a a Data presented as number (%) or median (IQR), as appropriate b Kidney Disease Outcomes Quality Initiative (KDOQI) chronic kidney disease stages 3–5 or GFR < 60 mL/min or on chronic dialysis c History of Clostridioides difficile infection d Immunosuppression factors: neutropenia (absolute neutrophil count < 500); splenectomy (functional or surgical); high dose corticosteroids (≥ prednisone 20 mg/day or equivalent) Abbreviations: BMI, body mass index; LTAC, long-term acute care; NH/LTC, nursing home/long-term care facility; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, sequential organ failure assessment; COPD, chronic obstructive pulmonary disease Intra-abdominal and skin and soft tissue infections comprised the majority of infection types, followed by osteomyelitis, septic arthritis, or PJI (Table 2). E. faecalis was present in 44% of infections, and E. faecium was isolated in 58% of patients, with both organisms isolated in two patients. Nearly half (49%) of all enterococcal isolates were VRE (73% E. faecium, 19% E. faecalis). ERV-specific susceptibilities were not available for any Enterococcus spp. isolates included in this analysis. A summary of antimicrobial susceptibilities is available in Fig. 1. Most (80%) infections were polymicrobial. Other common coinfecting pathogens included Enterobacterales (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, etc.), followed by Staphylococcus aureus, Stenotrophomonas maltophilia, and Acinetobacter baumannii. 55% of patients received antibiotics active against Enterococcus spp. prior to the initiation of ERV, with the rationale for switching to ERV in most cases being consolidation of antibiotic regimen (72%), presence of multidrug resistance (12%), and/or safety concerns with the first-line agent (10%). The median time to initiation of ERV was 118 h from index culture. The median ERV duration was 9.5 days, and 11% of patients received combination therapy with another active anti-enterococcal antibiotic. Table 2Clinical course and treatment characteristics (n = 100)aParameterValue ICU admissions At least one ICU admission during hospitalization59 (59.0) Patients with > 1 ICU admission during hospitalization12 (12.0) In ICU at index culture collection24 (24.0) ICU length of stay (days)23.5 (12.0–58.8) Culture specimen b Fluid29 (29.0) Wound26 (26.0) Blood26 (26.0) Tissue26 (26.0) Urine5 (5.0) Respiratory culture specimen5 (5.0) Sputum3 (3.0) Aspirate1 (1.0) Bronchoalveolar lavage1 (1.0) Bone3 (3.0) Primary source of infection Intra-abdominal41 (41.0) Skin and soft tissue29 (29.0) Osteomyelitis / septic arthritis / PJI13 (13.0) Urinary tract5 (5.0) Pneumonia4 (4.0) Primary bacteremia2 (2.0) Infective endocarditis1 (1.0) Other4 (4.0) Unknown1 (1.0) Enterococcus species Enterococcus faecalis 44 (44.0) Enterococcus faecium 58 (58.0)Polymicrobial infection80 (80.0) Additional pathogens targeted by ERV c Escherichia coli 24 (24.0) Klebsiella pneumoniae 19 (19.0) Enterobacter cloacae 16 (16.0) Staphylococcus aureus 14 (14.0) MRSA 9 (9.0) Stenotrophomonas maltophilia 9 (9.0) Acinetobacter baumannii-calcoaceticus complex7 (7.0) Bacteroides spp. 5 (5.0) Other Staphylococcus spp.4 (4.0) Streptococcus spp.4 (4.0) Enterobacter aerogenes 3 (3.0) Pseudomonas aeruginosa 2 (2.0) Citrobacter freundii 2 (2.0) Klebsiella oxytoca 2 (2.0) Morganella morganiii 2 (2.0) Providencia stuartii 2 (2.0) Proteus mirabilis 1 (1.0) Clostridium perfringens 1 (1.0) Pseudomonas fluorescens 1 (1.0) Other7 (7.0)ID consult96 (96.0)Surgical interventiond66 (66.0) Active therapy before ERV e 55 (55.0) Vancomycin22 (22.0) Linezolid12 (12.0) Piperacillin-tazobactam11 (11.0) Daptomycin8 (8.0) Tedizolid2 (2.0)ERV treatment characteristics Rationale for ERV use Consolidation of regimen72 (72.0) Preferred treatment of MDR organism12 (12.0) Safety concerns or intolerance to first-line agent10 (10.0) Lack of oral access7 (7.0) Double CRE coverage7 (6.0) Efficacy concerns with first-line agent3 (3.0) Unknown / Not documented4 (4.0) ERV regimens Dose 1 mg/kg every 12 h96 (96.0) 1 mg/kg every 12 h x 1 day, then 1 mg/kg daily2 (2.0) 1.5 mg/kg daily1 (1.0) 0.5 mg/kg every 12 h1 (1.0)Time to ERV start (hours)118.0 (45.0–258.8)ERV duration of therapy (days)9.5 (4.0–21.0) Combination therapy f 11 (11.0) Daptomycin5 (5.0) Vancomycin3 (3.0) Ampicillin1 (1.0) Linezolid1 (1.0) Tedizolid1 (1.0) Piperacillin-tazobactam1 (1.0)ERV switched to another agent23 (23.0) Discharge disposition Home35 (35.0) LTAC27 (27.0) Death24 (24.0) Hospice8 (8.0) Rehab center6 (6.0)Hospital length of stay (days)30.0 (14.3–46.8)a Data presented as number (%) or median (IQR) as appropriateb Index organism(s) isolated from ≥ 1 source in some casesc Patients may have ≥ 1 additional pathogen isolated in cultured Surgical intervention: incision & drainage (n = 27), debridement (n = 16), IV catheter removal (n =5), amputation (n =4), other invasive device removal (n =1), other (n =26). Some patients underwent > 1 surgical interventione Active therapy: Demonstrated in vitro susceptibilityf Concomitant therapy: Antibiotic with potential enterococcal activity administered for ≥ 48 continuous hours while the patient received eravacycline. One patient received daptomycin, then linezolid in combination with ERVAbbreviations: ICU, intensive care units; ID, infectious diseases; ERV, eravacycline; LTAC, long-term acute care Clinical course and treatment characteristics (n = 100)a a Data presented as number (%) or median (IQR) as appropriate b Index organism(s) isolated from ≥ 1 source in some cases c Patients may have ≥ 1 additional pathogen isolated in culture d Surgical intervention: incision & drainage (n = 27), debridement (n = 16), IV catheter removal (n =5), amputation (n =4), other invasive device removal (n =1), other (n =26). Some patients underwent > 1 surgical intervention e Active therapy: Demonstrated in vitro susceptibility f Concomitant therapy: Antibiotic with potential enterococcal activity administered for ≥ 48 continuous hours while the patient received eravacycline. One patient received daptomycin, then linezolid in combination with ERV Abbreviations: ICU, intensive care units; ID, infectious diseases; ERV, eravacycline; LTAC, long-term acute care Heatmap of antibiotic susceptibility of Enterococcus isolates treated with eravacycline. Green color indicates a higher percentage of susceptible isolates, while yellow indicates lower. Susceptibility determined utilizing breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) (M100, 34th edition) [37]. Isolates with minimum inhibitory concentrations (MICs) classified as susceptible or susceptible dose-dependent were deemed susceptible, while MICs categorized as intermediate or resistant were considered non-susceptible. A tigecycline breakpoint of ≤ 0.25 µg/mL was used to determine susceptibility [38] The primary objective of clinical cure was achieved in 77% of patients. With respect to secondary outcomes, 17% of patients died within 30 days of index culture, with 12% of patients experiencing infection-related mortality (Table 3). The 30-day hospital readmission rate was 14% with a microbiologic recurrence rate of 4%. Among patients treated with ERV for the treatment of enterococcal bacteremia (n = 26), the clinical cure rate was 73%. A comparable clinical cure rate was observed in patients receiving ERV monotherapy for a monomicrobial enterococcal infections (73%, n = 11). The incidence of TEAEs associated with ERV was low, with 92% of patients experiencing no adverse events. Five patients experienced gastrointestinal intolerance, and 3 patients experienced transaminitis. Two of these incidents resulted in the cessation of ERV: one due to gastrointestinal intolerance and the other due to transaminitis. Table 3Clinical outcomes and tolerability (n = 100)aParameterValueClinical cureb77 (77.0)30-day all-cause mortality17 (17.0)30-day infection-related mortality12 (12.0)Absence of microbiological recurrencec96 (96.0) Microbiological recurrence 4 (4.0) Symptomatic4 (4.0) Treated with antibiotic(s)4 (4.0) Hospital readmission 30-day14 (14.0) 60-dayd12 (13.9)Positive culture on readmission2 (2.0)ERV on readmission2 (2.0) Treatment-emergent adverse events Gastrointestinal intolerancee5 (5.0) Transaminitis3 (3.0) None92 (92.0) ERV discontinuation secondary to an adverse event Gastrointestinal intolerancee1 (1.0) Transaminitis1 (1.0)a Data are presented as number (%)b Clinical cure: The resolution of infectious signs and symptoms including infection-related abnormal white blood cell count/temperature or as documented by the physician in clinical notesc Microbiological recurrence: an isolate of the same bacteria (at species level) from the same culture source taken after a negative cultured Patients with a 30-day readmission were muted from 60-day readmission totale Gastrointestinal intolerance defined as nausea, vomiting, and/or diarrhea Clinical outcomes and tolerability (n = 100)a a Data are presented as number (%) b Clinical cure: The resolution of infectious signs and symptoms including infection-related abnormal white blood cell count/temperature or as documented by the physician in clinical notes c Microbiological recurrence: an isolate of the same bacteria (at species level) from the same culture source taken after a negative culture d Patients with a 30-day readmission were muted from 60-day readmission total e Gastrointestinal intolerance defined as nausea, vomiting, and/or diarrhea Discussion While the safe and effective use of ERV has been described previously, few real-world data exist solely assessing its use in enterococcal infections. In this study, we describe the use of ERV in patients with infections due to Enterococcus spp. It is notable that a majority of patients included in this analysis had polymicrobial infections, where it may be difficult to discern the primary causative organism of the infection. However, the demonstrated efficacy of ERV for the treatment of polymicrobial infections in this study underscores its utility attributable to its broad spectrum of activity across a diverse array of Gram-positive and Gram-negative organisms. This analysis revealed that the predominant usage of ERV was for consolidation of the patient’s antimicrobial regimen, which further highlights its place in therapy. Consolidation from several antibiotics to a single antibiotic administered twice daily reduces nursing workload, saves vital intravenous catheter occupancy time (allowing for more timely administration of other drugs), and reduces antibiotic exposure, mitigating the risk for the development of antimicrobial resistance. In this real-world study, we included several patient populations that were excluded from the INGITE-1 and IGNITE-4 trials. These trials notably excluded any severe illness (including septic shock), patients with creatinine clearance rates ≤ 50 mL/min, patients with signs of significant hepatic disease, and immunocompromised patients (IGNITE-4 only) [29, 30]. In our study, 18% of patients had moderate to severe chronic kidney disease, 11% of patients had moderate to severe hepatic disease, and 19% of patients were immunocompromised. Furthermore, 24% of patients were in the ICU at the time of index culture collection. Despite this, clinical efficacy and safety were demonstrated, underscoring the utility of real-world studies such as this one. The safety of ERV in real-world applications was demonstrated in this study, as evidenced by of the low incidence of TEAEs leading to discontinuation. Moreover, we found that the third most prevalent rationale for selecting ERV was due to safety concerns with the first-line anti-enterococcal agent. The safety of ERV in this study is noteworthy, considering the safety profiles of other frequently used agents for treating enterococcal infections. Vancomycin is well-known for its potential to cause nephrotoxicity and infusion syndromes [39]. Daptomycin, the most common first-line agent for the treatment of VRE, is associated with elevations in creatine phosphokinase and, more rarely, myopathy and rhabdomyolysis, although these risks are mitigated with once-daily dosing [40–42]. Although rare, the development of daptomycin-induced eosinophilic pneumonia is well-documented in the literature [43]. These toxicities appear to be dose-dependent, raising concerns given higher daptomycin doses are often required for effective anti-enterococcal activity [44–46]. Linezolid, another common treatment option for VRE, more frequently raises safety concerns relating to myelosuppression, particularly with durations exceeding 10 days [13, 14]. This may not be tolerable in patients who are immunocompromised or who are already at risk for myelosuppression. Furthermore, the risk for serotonin syndrome due to linezolid, particularly when paired with commonly prescribed medications such as selective serotonin reuptake inhibitors (SSRIs), remains a concern [13]. The efficacy of linezolid for the treatment of VRE bacteremia has also been questioned. One retrospective study of 644 patients comparing linezolid to daptomycin for the treatment of VRE bacteremia found an increased risk of 30-day mortality and microbiologic failure in the linezolid group, although previous meta-analyses conflict with these results [47, 48]. Other third generation tetracycline antibiotics may be considered for the treatment of enterococcal infections, including tigecycline and omadacycline [49]. Tigecycline has been associated with poor outcomes when used for the treatment of systemic infections; however, these data primarily arise from studies utilizing the conventional 100 mg total daily dose (TDD) [50, 51]. Studies assessing the efficacy of high dose (200 mg TDD) tigecycline in Enterobacterales found similar efficacy to comparator treatments, and data indicate that this may extend to the treatment of enterococcal infections [51, 52]. However, high dose tigecycline therapy may be limited by gastrointestinal adverse effects [53]. This and other studies demonstrate that ERV and omadacycline are associated with fewer adverse events than tigecycline [28, 54]. Few clinical studies exist that assess the efficacy and safety of omadacycline for the treatment of enterococcal infections specifically; therefore, it is difficult to draw definitive conclusions to support its use in this setting. This is the first study to our knowledge assessing the efficacy and safety or eravacycline for the treatment of enterococcal infections. Limitations of this analysis include its retrospective nature and the lack of comparative analysis to other common anti-enterococcal antibiotics. Moreover, the clinical significance of Enterococcus spp. in intra-abdominal infections and pneumonia is ambiguous and the necessity of treating these organisms remains a topic of debate [55, 56]. Therefore, our findings should be interpreted with caution, as we cannot definitively determine whether the enterococcal organisms of interest represent primary pathogens or colonizing organisms in some cases. Time to anti-enterococcal therapy has been demonstrated to impact patient outcomes in VRE bloodstream infections [57]. In cases where ERV was administered as salvage therapy, we were unable to confirm the timing of the initial active anti-enterococcal therapy relative to the index culture, which represents a limitation of our study. More extensive and comprehensive investigations are required to draw definitive conclusions regarding the efficacy of ERV compared to other agents in treating enterococcal infections, as well as to determine factors that may predict clinical success with ERV. Conclusions Infections caused by Enterococcus spp. are difficult to treat as a result of their ability to persist and propensity for antibiotic resistance. Here we demonstrate the safety and efficacy of eravacycline for the treatment of infections caused by Enterococcus faecalis and Enterococcus faecium, including VRE phenotypes. Abbreviations Vancomycin-resistant Enterococci Eravacycline Prosthetic joint infection United States Centers for Disease Control and Prevention Complicated intra-abdominal infection Multidrug-resistant Methicillin-resistant Staphylococcus aureus Extended-spectrum β-lactamase Carbapenemase-producing Enterobacterales Test of cure Intensive care unit Treatment-emergent adverse event Acute Physiology and Chronic Health Evaluation II score Charlson Comorbidity Index Interquartile range Body mass index Total daily dose Author contributions SRV: conceptualization, methodology, formal analysis, data curation, writing – original draft, visualization; AJKC: conceptualization, investigation, data curation, writing – review & editing, project administration; SA: conceptualization, investigation, data curation, project administration; KCM: investigation, writing – review & editing; SLKB: investigation; JA: investigation; MAK: investigation; KCC: investigation; ALVH: investigation; NBP: investigation, writing – review & editing, JA: investigation; AD: investigation; MB: investigation, writing – review & editing, MPV: investigation; ST: investigation; TG: investigation; BMJ: investigation, writing – review & editing; BMP: investigation; MRS: investigation; RC: investigation, writing – review & editing; SRH: investigation, writing – review & editing, CJ: investigation, data curation, project administration; MA: methodology, data curation, writing – review & editing; MJR: conceptualization, methodology, resources, writing – review & editing, supervision, project administration, funding acquisition. Funding This study was funded by an investigator-initiated grant from Innoviva Specialty Therapeutics, Inc. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Human ethics and consent to participate This retrospective study was conducted using de-identified data and did not involve direct patient contact. As such, informed consent was waived by the Institutional Review Board. This study was reviewed and approved by the institutional review boards at Wayne State University (052019MP2X, protocol number 1905002252) and at each participating site and was conducted in accordance with the Declaration of Helsinki. Competing interests MJR has received grant support/consulted or has participated on a speaker bureau for AbbVie, Innoviva, Melinta, Merck, and Shionogi. BMJ has consulted for or participated on a speaker bureau for Innovivia, AbbVie, Paratek, and Ferring. KCM has received grant support/consulted for Melintia, Merck, and Shionogi. All other authors declare no conflicts of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.